Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions
NCT06648317 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2024-11-25
Summary
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with lung lesions.
Conditions
- Lung Cancer, Non-Small Cell
- Lung Infection
Interventions
- OTHER
-
FDG-PET
All study participants will undergo 18F-FDG PET/CT scan within 1 week
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
lead OTHER
Principal Investigators
-
Nan Li, MD · Peking University Cnacer Hospital & Institute
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-21
- Primary Completion
- 2025-03-01
- Completion
- 2025-12-01
Countries
- China
Study Locations
More Related Trials
-
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
NCT05321316 ·Status: RECRUITING ·Phase: NA
-
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
NCT05156515 ·Status: UNKNOWN ·Phase: NA
-
18F-LN1 PET/CT in Urothelial Carcinomas
NCT06120413 ·Status: RECRUITING
-
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
NCT05543954 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
NCT06844110 ·Status: RECRUITING ·Phase: NA
-
[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer
NCT06165874 ·Status: RECRUITING ·Phase: NA
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT06843629 ·Status: RECRUITING
-
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection
NCT06945432 ·Status: COMPLETED
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Research for the Molecular Imaging of the PD-L1 Targeting Tracer
NCT04304066 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors
NCT05322512 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 Expression
NCT07319130 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Influence of PET/CT Radiomic Features on the Outcome of Lung Cancer Patients
NCT03648151 ·Status: COMPLETED
-
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT06646952 ·Status: RECRUITING
-
First Human Trial of Targeting MDM2/MDMX PET Imaging
NCT06443762 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
NCT06638034 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
NCT02511197 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT07144085 ·Status: RECRUITING ·Phase: PHASE1
-
CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors
NCT06720298 ·Status: NOT_YET_RECRUITING
-
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
NCT07023640 ·Status: RECRUITING ·Phase: NA
-
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
NCT05814835 ·Status: COMPLETED ·Phase: PHASE1